Stella's acquisition of Field Trip Health's U.S. assets takes center stage, revealing a strategic merger that combines Stella's innovative Stellate Ganglion Block technique and physical treatement centers with Field Trip Health's experience  and infrastructure for deliverying in psychedelic-enhanced psychotherapy. 

Dr. Eugene Lipov and Mujeeb Jafferi delve into the nuances and power of combining treatments, the potential of telepsychiatry, and the future trajectory of mental health care, emphasizing the critical role of data-driven approaches and the need for broadened accessibility in the realm of psychiatric treatments.

Timestamps and Show-notes From the Episode:
‍

3:33: Dr. Eugene Lipov discusses the invention of the Stella Ganglion block.

‍

5:33: Mujeeb Jafferi shares the founding story of Field Trip Health.

‍

8:53: The origin story of how Field Trip and Stella met and how their partnership evolved.

‍

10:03: Discussion about Field Trip's rapid expansion and subsequent challenges. Transition from a B2B to a B2C model during the pandemic.

‍

16:03: Challenges faced while opening the first Stella center, especially right before the pandemic.

‍

18:13: Comparison of various treatments, with a focus on the Stella Ganglion block vs. TMS and ketamine. The increasing cultural awareness of ketamine.

‍

19:53: Introduction of at-home ketamine services due to new telehealth laws. The partnership with NeuLife and the effectiveness of ketamine in different settings.

‍

24:55: Dr. Lipov talks about the merger of Stella and Field Trip Health. He discusses the benefits of integration and the combination of treatments.

‍

29:53: Mujeeb Jafferi's concerns about the merger, especially regarding the preservation of treatment protocols and quality of care.

‍

32:18: Introduction of a new CTO and the technological innovations in place, including a custom patient portal.

‍

35:43: A deep dive into the design and user experience of the Field Trip app.

‍

38:23: Discussion about insurance coverage for different treatments, with a focus on Stella Ganglion blocks and ketamine.

‍

45:03: The importance of data collection through measurement-based care and related research.

‍

46:53: Dr. Eugene Lipov shares insights on epigenetics and its potential to reverse aging.

‍

47:33: Discussion on self-funded employer plans, with a focus on advocating for covering novel treatments.

‍

53:23: Speculation on the evolution of the Field Trip brand after the merger, emphasizing company name, people, and products.

Brought to you by: Osmind.org, the #1 EHR for the modern private psychiatry practice